Chronic hepatitis trials
- Reported quantity
- 1.6 mg subcutaneously
- Frequency
- Twice weekly
- Study duration
- 6–12 months
1.6 mg twice weekly is the single most repeated figure in this literature.
Protocols · Immune
Thymosin Alpha-1: literature-reported ranges
Thymosin alpha-1 has decades of human data from hepatitis B and C trials, sepsis studies and vaccine-adjuvant research, and is a licensed medicine in a number of countries. Its reported figures are unusually stable across studies.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
- Class
- 28-amino-acid thymic peptide
- Reported half-life
- Approximately 2 hours
- Routes used in the literature
- Subcutaneous in essentially all human studies
- Also written as
- —
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Sepsis and critical-care studies
- Reported quantity
- 1.6 mg
- Frequency
- Twice daily initially, tapering to once daily
- Study duration
- 5–7 days
Lymphocyte counts and mortality were the reported endpoints.
Vaccine adjuvant arms
- Reported quantity
- 1.6 mg
- Frequency
- Twice weekly around vaccination
- Study duration
- 4 weeks
Antibody titre response was the measured outcome.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Thymosin Alpha-1 · 10 mg Vial
Thymosin Alpha-1 is dosed at 300 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.
- Reconstitute
- Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
- Typical daily range
- 300–500 mcg once daily (gradual titration).
- Easy measuring
- At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
- Storage
- Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F); after reconstitution, refrigerate and use within 7 days.
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 300 mcg (0.3 mg) | 9 units (0.09 mL) |
| Weeks 2–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
Reconstitution maths
A 10 mg vial in 5 mL of bacteriostatic water gives 2 mg/mL; 0.8 mL draws 1.6 mg.
Open the reconstitution calculatorHow to read these figures
- Immune-modulating peptides behave differently in immunocompetent and immunosuppressed models — the trial populations matter.
- Acetate salt content varies between manufacturers and affects the true peptide mass per vial.
- Licensed product and research-grade powder are not equivalent materials.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
- [1]The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Wu J, Zhou L, Liu J, et al. · Crit Care · 2013 · PMC4056079
Patients with severe sepsis received subcutaneous thymosin alpha 1 at 1.6 mg twice daily for 7 days as adjunctive therapy in a randomized controlled trial.
View the record - [2]The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Wu J, Pei F, Zhou L, et al. · BMJ · 2025 · DOI 10.1136/bmj-2024-082583
Phase 3 trial in which sepsis patients received subcutaneous thymosin alpha 1 twice daily over a defined treatment course to assess 28-day mortality.
View the record - [3]A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients
SciClone/COVID-19 study group · Int J Infect Dis (phase III report) · 2022 · PMID 36042753
Moderate-to-severe COVID-19 patients received subcutaneous thymosin alpha 1 as add-on therapy at a defined dosing schedule alongside standard of care.
View the record
Search the databases yourself
Read the Thymosin Alpha-1 research briefOther immune compounds
AdamaxCyclic Semax analogue (cyclo-prolylglycine related)KPVα-MSH C-terminal tripeptideLL-3737-amino-acid cathelicidin antimicrobial peptideThymalinThymic peptide extract preparation
All research protocolsPeptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.